Prevention of antibiotic-nonsusceptible streptococcus pneumoniae with conjugate vaccines

Lee M. Hampton; Monica M. Farley; William Schaffner; Ann Thomas; Arthur Reingold; Lee H. Harrison; Ruth Lynfield; Nancy M. Bennett; Susan Petit; Kenneth Gershman; Joan Baumbach; Bernard Beall; James Jorgensen; Anita Glennen; Elizabeth R. Zell; Matthew Moore

doi:10.1093/infdis/jir755

Prevention of antibiotic-nonsusceptible streptococcus pneumoniae with conjugate vaccines

Lee M. Hampton, Monica M. Farley, William Schaffner, Ann Thomas, Arthur Reingold, Lee H. Harrison, Ruth Lynfield, Nancy M. Bennett, Susan Petit, Kenneth Gershman, Joan Baumbach, Bernard Beall, James Jorgensen, Anita Glennen, Elizabeth R. Zell, Matthew Moore

Pathology

Research output: Contribution to journal › Article › peer-review

78 Scopus citations

Abstract

Background. Streptococcus pneumoniae (pneumococcus) caused approximately 44000 US invasive pneumococcal disease (IPD) cases in 2008. Antibiotic nonsusceptibility complicates IPD treatment. Using penicillin susceptibility breakpoints adopted in 2008, we evaluated antibiotic-nonsusceptible IPD trends in light of the introductions of a 7-valent pneumococcal conjugate vaccine (PCV7) in 2000 and a 13-valent pneumococcal conjugate vaccine (PCV13) in 2010. Methods. IPD cases were defined by isolation of pneumococcus from a normally sterile site in individuals residing in Active Bacterial Core surveillance (ABCs) areas during 1998-2008. Pneumococci were serotyped and tested for antibiotic susceptibility using broth microdilution. Results. During 1998-2008, ABCs identified 43198 IPD cases. Penicillin-nonsusceptible strains caused 6%-14% of IPD cases, depending on age. Between 1998-1999 and 2008, penicillin-nonsusceptible IPD rates declined 64% for children aged <5 years (12.1-4.4 cases per 100000), and 45% for adults aged ≥65 (4.8-2.6 cases per 100000). Rates of IPD nonsusceptible to multiple antibiotics mirrored these trends. During 2007-2008, serotypes in PCV13 but not PCV7 caused 78%-97% of penicillin-nonsusceptible IPD, depending on age. Conclusions. Antibiotic-nonsusceptible IPD rates remain below pre-PCV7 rates for children <5 and adults ≥65 years old. PCV13 vaccines hold promise for further nonsusceptibility reductions.

Original language	English (US)
Pages (from-to)	401-411
Number of pages	11
Journal	Journal of Infectious Diseases
Volume	205
Issue number	3
DOIs	https://doi.org/10.1093/infdis/jir755
State	Published - Feb 1 2012

ASJC Scopus subject areas

Immunology and Allergy
Infectious Diseases

Access to Document

10.1093/infdis/jir755

Fingerprint Dive into the research topics of 'Prevention of antibiotic-nonsusceptible streptococcus pneumoniae with conjugate vaccines'. Together they form a unique fingerprint.

Cite this

Hampton, L. M., Farley, M. M., Schaffner, W., Thomas, A., Reingold, A., Harrison, L. H., Lynfield, R., Bennett, N. M., Petit, S., Gershman, K., Baumbach, J., Beall, B., Jorgensen, J., Glennen, A., Zell, E. R., & Moore, M. (2012). Prevention of antibiotic-nonsusceptible streptococcus pneumoniae with conjugate vaccines. Journal of Infectious Diseases, 205(3), 401-411. https://doi.org/10.1093/infdis/jir755

Prevention of antibiotic-nonsusceptible streptococcus pneumoniae with conjugate vaccines. / Hampton, Lee M.; Farley, Monica M.; Schaffner, William; Thomas, Ann; Reingold, Arthur; Harrison, Lee H.; Lynfield, Ruth; Bennett, Nancy M.; Petit, Susan; Gershman, Kenneth; Baumbach, Joan; Beall, Bernard; Jorgensen, James; Glennen, Anita; Zell, Elizabeth R.; Moore, Matthew.

In: Journal of Infectious Diseases, Vol. 205, No. 3, 01.02.2012, p. 401-411.

Research output: Contribution to journal › Article › peer-review

Hampton, LM, Farley, MM, Schaffner, W, Thomas, A, Reingold, A, Harrison, LH, Lynfield, R, Bennett, NM, Petit, S, Gershman, K, Baumbach, J, Beall, B, Jorgensen, J, Glennen, A, Zell, ER & Moore, M 2012, 'Prevention of antibiotic-nonsusceptible streptococcus pneumoniae with conjugate vaccines', Journal of Infectious Diseases, vol. 205, no. 3, pp. 401-411. https://doi.org/10.1093/infdis/jir755

Hampton, Lee M. ; Farley, Monica M. ; Schaffner, William ; Thomas, Ann ; Reingold, Arthur ; Harrison, Lee H. ; Lynfield, Ruth ; Bennett, Nancy M. ; Petit, Susan ; Gershman, Kenneth ; Baumbach, Joan ; Beall, Bernard ; Jorgensen, James ; Glennen, Anita ; Zell, Elizabeth R. ; Moore, Matthew. / Prevention of antibiotic-nonsusceptible streptococcus pneumoniae with conjugate vaccines. In: Journal of Infectious Diseases. 2012 ; Vol. 205, No. 3. pp. 401-411.

@article{7612f1ea536441699023cf192db50a92,

title = "Prevention of antibiotic-nonsusceptible streptococcus pneumoniae with conjugate vaccines",

abstract = "Background. Streptococcus pneumoniae (pneumococcus) caused approximately 44000 US invasive pneumococcal disease (IPD) cases in 2008. Antibiotic nonsusceptibility complicates IPD treatment. Using penicillin susceptibility breakpoints adopted in 2008, we evaluated antibiotic-nonsusceptible IPD trends in light of the introductions of a 7-valent pneumococcal conjugate vaccine (PCV7) in 2000 and a 13-valent pneumococcal conjugate vaccine (PCV13) in 2010. Methods. IPD cases were defined by isolation of pneumococcus from a normally sterile site in individuals residing in Active Bacterial Core surveillance (ABCs) areas during 1998-2008. Pneumococci were serotyped and tested for antibiotic susceptibility using broth microdilution. Results. During 1998-2008, ABCs identified 43198 IPD cases. Penicillin-nonsusceptible strains caused 6%-14% of IPD cases, depending on age. Between 1998-1999 and 2008, penicillin-nonsusceptible IPD rates declined 64% for children aged <5 years (12.1-4.4 cases per 100000), and 45% for adults aged ≥65 (4.8-2.6 cases per 100000). Rates of IPD nonsusceptible to multiple antibiotics mirrored these trends. During 2007-2008, serotypes in PCV13 but not PCV7 caused 78%-97% of penicillin-nonsusceptible IPD, depending on age. Conclusions. Antibiotic-nonsusceptible IPD rates remain below pre-PCV7 rates for children <5 and adults ≥65 years old. PCV13 vaccines hold promise for further nonsusceptibility reductions.",

author = "Hampton, {Lee M.} and Farley, {Monica M.} and William Schaffner and Ann Thomas and Arthur Reingold and Harrison, {Lee H.} and Ruth Lynfield and Bennett, {Nancy M.} and Susan Petit and Kenneth Gershman and Joan Baumbach and Bernard Beall and James Jorgensen and Anita Glennen and Zell, {Elizabeth R.} and Matthew Moore",

note = "Funding Information: Financial support. This work was supported by the Emerging Infections Programs and the Office of Antimicrobial Resistance of the Centers for Disease Control and Prevention. The Centers for Disease Control and Prevention{\textquoteright}s Emerging Infections Programs provided funding but made no other contributions to the design and conduct of this study; the collection, management, analysis, and interpretation of the data; or the preparation, review, or approval of this manuscript. Funding Information: Potential conflicts of interest. W. S. has served as a consultant to Pfizer, Novartis, GSK, Sanofi-Pasteur, and Dynavex, and is a member of Data Safety Monitoring Boards for Merck. L. H. H. has served as a consultant to and received lecture fees from Merck and Pfizer. J. H. J. has been a member of advisory boards for BD Microbiology Systems and for Rib-X Pharmaceuticals and has received research funding from BD, bioMerieux, Merck, Pfizer, and Siemens Healthcare. E. Z. owns stock in Pfizer, Merck, and Johnson and Johnson. All other authors report no potential conflicts.",

year = "2012",

month = feb,

day = "1",

doi = "10.1093/infdis/jir755",

language = "English (US)",

volume = "205",

pages = "401--411",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "3",

}

TY - JOUR

T1 - Prevention of antibiotic-nonsusceptible streptococcus pneumoniae with conjugate vaccines

AU - Hampton, Lee M.

AU - Farley, Monica M.

AU - Schaffner, William

AU - Thomas, Ann

AU - Reingold, Arthur

AU - Harrison, Lee H.

AU - Lynfield, Ruth

AU - Bennett, Nancy M.

AU - Petit, Susan

AU - Gershman, Kenneth

AU - Baumbach, Joan

AU - Beall, Bernard

AU - Jorgensen, James

AU - Glennen, Anita

AU - Zell, Elizabeth R.

AU - Moore, Matthew

N1 - Funding Information: Financial support. This work was supported by the Emerging Infections Programs and the Office of Antimicrobial Resistance of the Centers for Disease Control and Prevention. The Centers for Disease Control and Prevention’s Emerging Infections Programs provided funding but made no other contributions to the design and conduct of this study; the collection, management, analysis, and interpretation of the data; or the preparation, review, or approval of this manuscript. Funding Information: Potential conflicts of interest. W. S. has served as a consultant to Pfizer, Novartis, GSK, Sanofi-Pasteur, and Dynavex, and is a member of Data Safety Monitoring Boards for Merck. L. H. H. has served as a consultant to and received lecture fees from Merck and Pfizer. J. H. J. has been a member of advisory boards for BD Microbiology Systems and for Rib-X Pharmaceuticals and has received research funding from BD, bioMerieux, Merck, Pfizer, and Siemens Healthcare. E. Z. owns stock in Pfizer, Merck, and Johnson and Johnson. All other authors report no potential conflicts.

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Background. Streptococcus pneumoniae (pneumococcus) caused approximately 44000 US invasive pneumococcal disease (IPD) cases in 2008. Antibiotic nonsusceptibility complicates IPD treatment. Using penicillin susceptibility breakpoints adopted in 2008, we evaluated antibiotic-nonsusceptible IPD trends in light of the introductions of a 7-valent pneumococcal conjugate vaccine (PCV7) in 2000 and a 13-valent pneumococcal conjugate vaccine (PCV13) in 2010. Methods. IPD cases were defined by isolation of pneumococcus from a normally sterile site in individuals residing in Active Bacterial Core surveillance (ABCs) areas during 1998-2008. Pneumococci were serotyped and tested for antibiotic susceptibility using broth microdilution. Results. During 1998-2008, ABCs identified 43198 IPD cases. Penicillin-nonsusceptible strains caused 6%-14% of IPD cases, depending on age. Between 1998-1999 and 2008, penicillin-nonsusceptible IPD rates declined 64% for children aged <5 years (12.1-4.4 cases per 100000), and 45% for adults aged ≥65 (4.8-2.6 cases per 100000). Rates of IPD nonsusceptible to multiple antibiotics mirrored these trends. During 2007-2008, serotypes in PCV13 but not PCV7 caused 78%-97% of penicillin-nonsusceptible IPD, depending on age. Conclusions. Antibiotic-nonsusceptible IPD rates remain below pre-PCV7 rates for children <5 and adults ≥65 years old. PCV13 vaccines hold promise for further nonsusceptibility reductions.

AB - Background. Streptococcus pneumoniae (pneumococcus) caused approximately 44000 US invasive pneumococcal disease (IPD) cases in 2008. Antibiotic nonsusceptibility complicates IPD treatment. Using penicillin susceptibility breakpoints adopted in 2008, we evaluated antibiotic-nonsusceptible IPD trends in light of the introductions of a 7-valent pneumococcal conjugate vaccine (PCV7) in 2000 and a 13-valent pneumococcal conjugate vaccine (PCV13) in 2010. Methods. IPD cases were defined by isolation of pneumococcus from a normally sterile site in individuals residing in Active Bacterial Core surveillance (ABCs) areas during 1998-2008. Pneumococci were serotyped and tested for antibiotic susceptibility using broth microdilution. Results. During 1998-2008, ABCs identified 43198 IPD cases. Penicillin-nonsusceptible strains caused 6%-14% of IPD cases, depending on age. Between 1998-1999 and 2008, penicillin-nonsusceptible IPD rates declined 64% for children aged <5 years (12.1-4.4 cases per 100000), and 45% for adults aged ≥65 (4.8-2.6 cases per 100000). Rates of IPD nonsusceptible to multiple antibiotics mirrored these trends. During 2007-2008, serotypes in PCV13 but not PCV7 caused 78%-97% of penicillin-nonsusceptible IPD, depending on age. Conclusions. Antibiotic-nonsusceptible IPD rates remain below pre-PCV7 rates for children <5 and adults ≥65 years old. PCV13 vaccines hold promise for further nonsusceptibility reductions.

UR - http://www.scopus.com/inward/record.url?scp=84855892497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855892497&partnerID=8YFLogxK

U2 - 10.1093/infdis/jir755

DO - 10.1093/infdis/jir755

M3 - Article

C2 - 22158567

AN - SCOPUS:84855892497

VL - 205

SP - 401

EP - 411

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 3

ER -